[
  {
    "question": "MSA pathology:",
    "option_a": "Iron deposition.",
    "option_b": "Glial cytoplasmic inclusions.",
    "option_c": "Neurofibrillary tangles.",
    "option_d": "Lewy bodies.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder that presents with a combination of parkinsonian features, cerebellar signs, and autonomic dysfunction. It belongs to the group of atypical parkinsonian syndromes, also known as synucleinopathies. The defining pathological hallmark of MSA is the presence of glial cytoplasmic inclusions (GCIs) that are immunoreactive for alpha-synuclein. This differentiates MSA from other neurodegenerative diseases such as Parkinson's disease (which is characterized by Lewy bodies) and tauopathies (which show neurofibrillary tangles). MSA patients often present with parkinsonism that is poorly responsive to levodopa, combined with significant autonomic failure (e.g., orthostatic hypotension, urinary incontinence) and occasionally cerebellar symptoms, depending on the subtype (MSA-P or MSA-C). Diagnosis is based on clinical criteria supported by imaging findings. Differential diagnoses include Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration. MRI may reveal features such as putaminal atrophy and, particularly in MSA-C, the 'hot cross bun' sign in the pons. Management is supportive and symptomatic. A levodopa challenge is common despite a blunted response. Autonomic symptoms are managed with supportive measures (e.g., fludrocortisone, midodrine). In pregnancy or lactation, therapy is individualized given the lack of robust safety data, and conservative management with monitoring is advised. Option A (Iron deposition) is not the defining pathology for MSA. Option B (Glial cytoplasmic inclusions) is the correct pathological hallmark. Option C (Neurofibrillary tangles) and Option D (Lewy bodies) are seen in Alzheimer\u2019s disease/tauopathies and Parkinson\u2019s disease/dementia with Lewy bodies, respectively. 1. MSA features include poor levodopa response and prominent autonomic dysfunction. 2. The 'hot cross bun' sign on MRI supports a diagnosis of MSA-C. 3. GCIs are the pathological hallmark of MSA. Recent studies continue to focus on the role of alpha-synuclein aggregation in oligodendrocytes as the central pathogenic mechanism in MSA, and experimental therapies targeting synucleinopathy are under investigation.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient on pramipexol for PD developed hallucination?",
    "option_a": "Stop pramipexol",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson's disease (PD) is primarily managed with dopaminergic therapies. Pramipexole, a dopamine agonist, is used to alleviate motor symptoms; however, dopaminergic medications can induce neuropsychiatric side effects such as hallucinations. Hallucinations in PD are thought to result from dopaminergic overstimulation in brain regions that modulate mood and perception. Pramipexole, by mimicking dopamine, can tip the balance in susceptible individuals, leading to psychosis-like symptoms. In PD patients, the emergence of hallucinations\u2014often visual in nature\u2014may signal excessive dopaminergic stimulation, and these symptoms are especially common in elderly patients or those with pre-existing cognitive impairment. Evaluation involves excluding alternative causes of hallucinations such as delirium, infection, or concomitant medications. A careful review of the patient\u2019s medication regimen is crucial in identifying iatrogenic causes. The foremost step in management is to reduce or discontinue the offending agent\u2014in this case, pramipexole. Subsequently, if hallucinations persist, clinicians may consider adding atypical antipsychotics such as quetiapine or pimavanserin that are better tolerated in PD. In pregnant or lactating patients, medication changes require careful risk-benefit analysis due to limited safety data; nonpharmacologic measures and minimal effective dosing are recommended. Option A (Stop pramipexole) is appropriate because the drug is a common culprit for inducing hallucinations in PD. Although dose reduction might be an alternative strategy, discontinuing or tapering the offending agent is the first recommended step in managing medication-induced psychosis. 1. Hallucinations in PD are often medication-induced and may resolve with a reduction in dopaminergic therapy. 2. Atypical antipsychotics (e.g., pimavanserin) can be added if symptoms persist after medication adjustment. 3. Always consider other contributory factors such as infections or metabolic disturbances when evaluating hallucinations in PD. Recent guidelines emphasize a stepwise reduction of dopaminergic medications in PD when psychosis occurs, with emerging evidence supporting the use of pimavanserin for treatment-resistant hallucinations.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Tic and ADHD:",
    "option_a": "Atomoxetine",
    "option_b": "Methylphenidate",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Attention Deficit Hyperactivity Disorder (ADHD) is commonly managed with stimulant medications, which are considered first-line treatments. Historically, there was concern that stimulants could exacerbate tic disorders; however, robust evidence has shown that stimulants, particularly methylphenidate, do not significantly worsen tics and are often preferred in patients with coexisting ADHD and tic disorders. ADHD is characterized by dysregulation of dopaminergic and noradrenergic neurotransmission. Stimulants like methylphenidate enhance synaptic dopamine and norepinephrine, thereby improving attention, impulse control, and hyperactivity. Tic disorders are thought to involve basal ganglia dysfunction, but current evidence indicates that the dopaminergic effects of stimulants do not necessarily aggravate the tic circuitry. Many children with ADHD may also exhibit tics (or even Tourette syndrome). In clinical practice, the presence of tics is not considered a contraindication to the use of stimulant medications. Both stimulants and nonstimulant agents (like atomoxetine) are effective, but stimulants typically offer a greater effect size. Diagnosis involves a detailed clinical history and physical examination. Differential diagnoses include anxiety disorders, learning disabilities, and other neurodevelopmental disorders. It is essential to distinguish whether tics are primary or medication-induced, but evidence supports the use of stimulants even in patients with chronic tic disorders. According to current guidelines, methylphenidate is considered the first-line treatment for ADHD, even in patients with comorbid tic disorders. If tics are severe or if there is a concern for tic exacerbation (which is rare), alternatives such as alpha-2 agonists (e.g., guanfacine or clonidine) or nonstimulant agents like atomoxetine may be considered. In pregnant or lactating patients, clinicians must weigh the benefits against potential risks; while data on methylphenidate remains limited, atomoxetine also lacks extensive safety data, so careful monitoring and shared decision-making are essential. Option A (Atomoxetine) is a nonstimulant that is safe in tic disorders but is generally considered second-line compared to stimulants. Option B (Methylphenidate) is recommended as the first-line therapy for ADHD and is not contraindicated in the presence of tics. Therefore, Option B is the correct choice based on current evidence. 1. Stimulants, particularly methylphenidate, remain the first-line treatment for ADHD even with coexisting tics. 2. Historical concerns regarding tic exacerbation from stimulants have been largely refuted by current research. 3. Alpha-2 agonists offer a dual benefit in managing both ADHD symptoms and tics, serving as an alternative if needed. Recent meta-analyses and clinical trials have consistently shown that methylphenidate does not worsen tic symptoms in most patients. Updated guidelines from pediatric and psychiatric associations support the safe use of stimulants in patients with comorbid tic disorders, reaffirming their role as first-line therapy.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "In PSP receiving Sinemet what will improve?",
    "option_a": "Rigidity",
    "option_b": "Bradykinesia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian syndrome distinct from Parkinson\u2019s disease. Although many motor symptoms overlap (rigidity, bradykinesia), PSP is characterized by prominent gait instability, early falls, and especially vertical supranuclear gaze palsy. Levodopa (Sinemet) is a mainstay for PD but is known to have only a modest and inconsistent benefit in PSP. PSP is associated with abnormal accumulation of tau protein (a 4-repeat tauopathy) primarily affecting the brainstem, basal ganglia, and cerebellum. This leads to degeneration in the regions involved in motor planning and eye movements. The limited dopaminergic responsiveness reflects that the pathology is not driven solely by dopamine deficiency, in contrast to idiopathic PD. Patients with PSP present with symmetric parkinsonism, early postural instability, and vertical gaze palsy. While rigidity is present, the degree of bradykinesia may occasionally be modestly improved by a trial of levodopa \u2013 even though the overall response is poor compared to PD. This mild improvement in bradykinesia, if seen, can sometimes help distinguish it from classical Parkinson\u2019s disease. The diagnosis of PSP is primarily clinical. Key differentials include Parkinson\u2019s disease (typically asymmetrical, with a resting tremor and sustained levodopa response), Multiple System Atrophy (with prominent autonomic failure), Corticobasal Degeneration (with asymmetric rigidity and apraxia), and vascular parkinsonism (which has a stepwise progression). MRI brain demonstrating midbrain atrophy (the \u2018hummingbird sign\u2019) can support the diagnosis. There is no disease\u2010modifying treatment for PSP. Management is largely supportive. A levodopa trial (Sinemet) is often attempted in order to assess any modest benefit for bradykinesia; however, most patients do not experience significant functional improvement. Supportive therapies such as physical therapy, speech therapy, and occupational therapy are pivotal. In pregnancy and lactation, the use of levodopa is generally considered when benefits outweigh risks; although it is typically categorized as relatively safe in PD, caution and close monitoring are recommended. Option A (Rigidity) is less likely to improve with Sinemet in PSP because the dopaminergic deficits in PSP are not primarily responsible for rigidity. Option B (Bradykinesia) is the best answer since, if any response is observed with levodopa in PSP, it tends to be seen as a modest improvement in bradykinesia rather than other features. 1. PSP is classically associated with vertical supranuclear gaze palsy and early falls. 2. A levodopa trial in PSP may yield a slight improvement in bradykinesia, but the overall response is poor compared to PD. 3. MRI findings such as midbrain atrophy (\u2018hummingbird sign\u2019) support the diagnosis. Recent research emphasizes tau as the pathological hallmark of PSP, and clinical trials targeting tau aggregation are ongoing. Despite these advances, treatment remains symptomatic with no established disease\u2010modifying options, reinforcing the limited and selective response to dopaminergic therapy.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has PD and excessive sleep with motor fluctuation, what to give?",
    "option_a": "Selegeline",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "In Parkinson\u2019s disease (PD), motor fluctuations may lead to inconsistent periods of mobility, often termed 'off' periods. Excessive daytime sleepiness (EDS) in PD can be multifactorial \u2013 from the disease process itself, side effects of dopaminergic therapy, or the fluctuations in motor performance. Adjunct strategies aim to smooth out these fluctuations while minimizing additional side effects. Motor fluctuations in PD result from the pulsatile stimulation of dopamine receptors due to intermittent levodopa dosing, leading to receptor sensitization changes. The resulting \u2018off\u2019 periods can contribute to secondary symptoms including drowsiness or sleep attacks. MAO-B inhibitors, such as selegiline, work by inhibiting the breakdown of dopamine, allowing for a more continuous dopaminergic stimulation and potentially reducing off time. Patients with PD experiencing motor fluctuations might exhibit excessive sleepiness during off periods, which can be misinterpreted as primary sleep disorder. By reducing the duration and severity of off periods, overall daytime alertness may improve. It is thus essential to address the motor fluctuations to help alleviate secondary symptoms such as EDS. When assessing a PD patient with excessive sleepiness, one must consider medication side effects (especially dopamine agonists), sleep disorders (like sleep apnea or REM behavior disorder), and the fluctuations in motor performance. Detailed history, medication review, and sometimes sleep studies are needed to differentiate these causes. The first-line approach in managing motor fluctuations involves optimizing the levodopa dosing schedule. Adjunctive medications such as MAO-B inhibitors (e.g., selegiline, rasagiline) are often added to extend the duration of the levodopa effect and reduce off time. Selegiline is typically considered in earlier fluctuations. Pregnancy and lactation considerations require caution as there is limited safety data on selegiline; its use in pregnant or lactating women should only be considered if the benefits clearly outweigh the potential risks and under specialist guidance. Option A (Selegiline) is the correct answer as it is a selective MAO-B inhibitor that can help reduce motor fluctuations by providing a smoother dopaminergic stimulation, thereby indirectly addressing the excessive sleepiness associated with off periods. The marked answer B is incorrect as it is blank and does not offer any therapeutic benefit. 1. MAO-B inhibitors are beneficial in reducing off periods in PD and can improve overall motor stability. 2. When patients report excessive daytime sleepiness, review the medication regimen to assess for fluctuation-related drowsiness versus primary sleep disorders. 3. Optimize levodopa therapy before considering additional medications for EDS. Recent guidelines continue to support the use of MAO-B inhibitors in managing early motor fluctuations. Ongoing studies also explore alternative approaches to manage EDS in PD, including wakefulness-promoting agents like modafinil, emphasizing a tailored approach based on individual symptomatology.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of PSP, what is the Dx?",
    "option_a": "nalysis, the hallmark features (vertical gaze palsy, early falls, and symmetric parkinsonism) point to PSP. Although the letter corresponding to PSP in the original set is not explicitly given in the options, the analysis indicates that PSP is the correct diagnostic label. The marked answer B is accepted as correct if option B represents PSP.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "This question presents a clinical scenario suggestive of an atypical parkinsonian syndrome. The key is to differentiate Progressive Supranuclear Palsy (PSP) from other parkinsonian disorders based on the clinical presentation. PSP is characterized by accumulation of abnormal tau protein in various brain regions including the brainstem, basal ganglia, and cerebellum. This tauopathy results in neuronal degeneration affecting eye movements, balance, and motor function. Patients with PSP typically present with symmetric bradykinesia, postural instability with early falls, and a classic vertical supranuclear gaze palsy. These features are distinct from Parkinson\u2019s disease, which often has an asymmetric onset and a robust response to levodopa. The diagnosis of PSP is clinical, supported by findings such as the \u2018hummingbird sign\u2019 on MRI. The main differentials include Parkinson\u2019s disease (asymmetric symptoms, resting tremor, good levodopa response), Multiple System Atrophy (autonomic failure, cerebellar signs), Corticobasal Degeneration (asymmetric rigidity, apraxia), and vascular parkinsonism (stepwise progression). There is no disease\u2010modifying therapy for PSP; treatment is supportive. Levodopa trials are often attempted but usually yield only minimal benefit. Management includes physical, occupational, and speech therapies. In pregnancy and lactation, due to the lack of specific treatments for PSP, supportive care is tailored individually, and potential medications are used with caution, balancing maternal benefits and fetal risks. Based on the clinical scenario and the differential diagnosis provided in the option analysis, the hallmark features (vertical gaze palsy, early falls, and symmetric parkinsonism) point to PSP. Although the letter corresponding to PSP in the original set is not explicitly given in the options, the analysis indicates that PSP is the correct diagnostic label. The marked answer B is accepted as correct if option B represents PSP. 1. A vertical supranuclear gaze palsy is highly indicative of PSP. 2. Early falls and postural instability are classic features that differentiate PSP from typical Parkinson\u2019s disease. 3. MRI can assist in the diagnosis with the midbrain atrophy sign (\u2018hummingbird sign\u2019). Current research is focused on tau-targeted therapies and biomarkers for PSP. However, treatment remains supportive, and recent guidelines emphasize early introduction of multidisciplinary care to manage symptoms and improve quality of life.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "PD with dystonia, not improving with treatment.",
    "option_a": "DBS of GPi",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) can be complicated by the development of dystonia, which may occur as a part of the disease process or as a side effect of long-term dopaminergic therapy. When medical therapy fails to adequately control dystonic symptoms, surgical interventions such as deep brain stimulation (DBS) become a consideration. Dystonia in PD arises due to dysfunction in the basal ganglia circuits. Over time, chronic intermittent stimulation by levodopa leads to maladaptive plasticity in these networks, resulting in abnormal, sustained muscle contractions and dystonic posturing. Patients with PD and refractory dystonia often experience painful, prolonged muscle contractions that do not respond to adjustments in medication. This can be particularly disabling and may occur either during off periods or as a part of levodopa-induced dyskinesia. The diagnosis of refractory dystonia in PD is clinical. It is important to rule out other causes of abnormal movements such as drug-induced dyskinesias. Neuroimaging and careful medication review help differentiate these conditions. Differential diagnoses include primary dystonia (which may respond better to DBS of the globus pallidus internus) and other forms of secondary dystonia. DBS is a well-established treatment for PD, particularly in patients with motor complications that are refractory to optimal medical therapy. While subthalamic nucleus (STN) DBS is commonly used for overall motor symptoms, DBS of the globus pallidus internus (GPi) is specifically effective for controlling dystonia. Surgical candidacy should be carefully assessed, and the procedure is generally considered after exhausting medical treatment options. In the context of pregnancy or lactation, elective surgical procedures like DBS are typically deferred unless absolutely necessary, and a multidisciplinary risk\u2013benefit analysis is critical. Option A (DBS of GPi) is correct because GPi stimulation has been shown to effectively reduce refractory dystonia in PD. Other possible options (not provided here) would likely include alternative medications or adjustments in dopaminergic therapy, which have proven ineffective in this scenario. 1. DBS of the GPi is particularly beneficial for refractory dystonia, both in primary dystonia and in PD-related dystonia. 2. Careful patient selection and pre-surgical evaluation are paramount to the success of DBS. 3. In advanced PD with motor complications, surgical options should be considered after optimal medical therapy has been reached. Recent studies and guidelines support the use of GPi DBS for managing dystonic symptoms in PD patients who do not respond to medication adjustments. Ongoing research is comparing the efficacy of different DBS targets, but current evidence firmly establishes GPi DBS as an effective treatment for refractory dystonia in PD.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "PD on multiple agents developed hallucination.",
    "option_a": "Stop amantadine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "In Parkinson\u2019s disease (PD), patients are often on multiple medications that may contribute to neuropsychiatric side effects such as visual hallucinations. Amantadine, used for managing dyskinesias, has known central anticholinergic effects that can precipitate hallucinations, especially in elderly patients. Amantadine\u2019s mechanism involves NMDA receptor antagonism and some anticholinergic properties. In susceptible PD patients, these pharmacological actions can disrupt normal cholinergic-dopaminergic balance, leading to sensory misperceptions and hallucinations. Moreover, polypharmacy increases the risk for such adverse events via cumulative effects on neurotransmission. Hallucinations are not uncommon in PD, particularly as the disease advances or when multiple dopaminergic medications are utilized. Clinically, patients may report visual hallucinations while retaining insight, but in more severe cases, they can progress to delusions. Recognizing drug-induced hallucinations is critical for preventing further cognitive decline. Differential diagnosis includes Parkinson\u2019s disease dementia, Lewy body dementia (which itself is characterized by hallucinations), and other medication-induced psychoses. A careful medication review and assessment of the timing of symptom onset relative to drug changes are essential to differentiate these conditions. First-line management involves a careful review of the patient's medication regimen. The guideline recommendation is to reduce or stop medications that may cause neuropsychiatric side effects. In this scenario, stopping amantadine is appropriate. If hallucinations persist or worsen, further adjustments may include reducing the dose of other dopaminergic agents or using low-dose atypical antipsychotics (eg, quetiapine or clozapine) with consideration to their safety profile in pregnancy and lactation. In pregnant or lactating patients, any medication adjustments should be weighed against the risks to the mother and fetus, using the lowest effective doses and alternative non-pharmacologic measures when possible. Option A (Stop amantadine) is correct because amantadine is a known contributor to hallucinations in PD due to its anticholinergic effects. Other options were not provided, but among the choices, eliminating the offending agent is the recommended first step. 1. Always reassess the medication regimen in PD patients who develop neuropsychiatric symptoms. 2. Amantadine-induced hallucinations are dose-dependent and more common in the elderly. 3. A gradual medication reduction can help determine the offending agent. Recent guidelines and studies from the Movement Disorder Society emphasize minimizing polypharmacy in PD. Current research supports reducing or discontinuing medications known to exacerbate hallucinations, with careful titration to maintain motor control while alleviating neuropsychiatric complications.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Hemifacial spasm scenario. Treatment?",
    "option_a": "Botox",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Hemifacial spasm is characterized by involuntary, irregular contractions of muscles on one side of the face, typically resulting from irritation or compression of the facial nerve. Botulinum toxin (Botox) is the mainstay of symptomatic treatment. The underlying mechanism often involves vascular compression of the facial nerve at the root exit zone, which leads to hyperexcitability and ectopic nerve firing. Botulinum toxin works by blocking the release of acetylcholine at the neuromuscular junction, thereby reducing muscle contractions. Patients generally present with intermittent, twitching contractions that initially may involve the orbicularis oculi and later spread to involve other facial muscles. The condition is usually unilateral and can worsen with stress or fatigue. Differential diagnoses include blepharospasm, facial myokymia, and focal motor seizures. A detailed clinical history and neurological examination are typically sufficient to distinguish hemifacial spasm; neuroimaging may be warranted to exclude structural lesions. First-line treatment is botulinum toxin injections, which provide targeted and effective symptom relief. In patients with contraindications (eg, pregnancy), the use of Botox is generally considered with caution, although reports suggest that when absolutely necessary and performed by experienced clinicians, localized injections may be used after a thorough risk-benefit analysis. Second-line treatment in refractory cases may involve microvascular decompression surgery. Option A (Botox) is correct. It is well established as the first-line treatment for hemifacial spasm. The absence of other options reinforces this choice. 1. Hemifacial spasm typically presents as unilateral facial twitching that may be task-specific. 2. Botulinum toxin injections provide significant symptom relief and are generally safe. 3. Microvascular decompression remains an option for refractory cases. Recent studies continue to support the use of botulinum toxin as the most effective, minimally invasive treatment for hemifacial spasm. Updated guidelines from neurology societies emphasize its efficacy and safety profile, including considerations for special populations.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "PD with motor function and dyskinesia.",
    "option_a": "Decrease Sinemet and add dopamine agonist",
    "option_b": ", the standard approach remains Option A.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "In Parkinson\u2019s disease (PD), dyskinesia is a common complication from long-term levodopa (Sinemet) therapy. When a patient exhibits good motor function but develops levodopa-induced dyskinesia, the management strategy often involves adjusting the levodopa dose while maintaining overall motor control. Levodopa-induced dyskinesias are thought to occur due to pulsatile stimulation of dopamine receptors, which over time leads to maladaptive plasticity and abnormal motor signaling. Reducing the peak dose can help minimize these involuntary movements while other medications help stabilize the dopaminergic tone. Clinically, patients may present with peak-dose dyskinesia, where involuntary movements occur at times of maximal levodopa concentration. This is distinct from 'off' periods where motor performance deteriorates due to low dopamine levels. Differentials include off-period dystonia, motor fluctuations, and other hyperkinetic movement disorders. A careful review of the timing of symptoms in relation to medication dosing helps clarify the diagnosis. The first-line management for a patient with dyskinesia and good motor control is to decrease the levodopa (Sinemet) dose to minimize peak-dose effects and add a dopamine agonist if needed to maintain motor function. Other strategies include using amantadine, a medication with antidyskinetic properties. In pregnancy or lactation, levodopa has a relatively better record compared to dopamine agonists; however, treatment modifications should be discussed with the patient, ensuring the lowest effective doses are used, and a multidisciplinary approach is taken to balance maternal benefits with fetal risks. Option A ('Decrease Sinemet and add dopamine agonist') is considered the appropriate strategy to mitigate dyskinesia while preserving motor control. The marked answer, Option B, is incorrect because it does not address the reduction in levodopa dosing which is pivotal in managing levodopa-induced dyskinesias. Without a clear rationale and lacking details for Option B, the standard approach remains Option A. 1. Levodopa-induced dyskinesias are typically managed by dose adjustment and optimizing drug formulations. 2. Adding a dopamine agonist can help maintain motor function when levodopa dose is reduced. 3. Amantadine is another therapeutic option specifically useful for managing dyskinesia. Recent guidelines from the Movement Disorder Society recommend a careful balance of dopaminergic therapies in PD. Studies have shown that adjusting levodopa dosing schedules and considering adjunctive therapies can effectively reduce dyskinesias, with current research exploring novel formulations and adjunct treatments.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient was in psychiatric hospital developed abnormal movement.",
    "option_a": "Tardive dyskinesia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Tardive dyskinesia is a hyperkinetic movement disorder that arises as a side effect from long-term use of dopamine receptor antagonists, typically antipsychotic medications. It is characterized by involuntary, repetitive movements, often affecting the face, lips, tongue, and sometimes the limbs. The underlying mechanism involves prolonged dopamine D2 receptor blockade, which leads to a compensatory upregulation and hypersensitivity of the dopaminergic system in the basal ganglia. This receptor supersensitivity results in the development of abnormal involuntary movements. Patients with tardive dyskinesia, especially those with a history of chronic antipsychotic use in a psychiatric setting, present with symptoms such as abnormal facial movements, lip smacking, tongue protrusion, or choreiform movements. Recognizing the temporal relationship between antipsychotic exposure and symptom onset is key. Differential diagnoses include drug-induced parkinsonism, acute dystonic reactions, and other extrapyramidal symptoms. A detailed medication history and symptom chronology are essential for diagnosis. Rating scales, such as the Abnormal Involuntary Movement Scale (AIMS), are often used to assess severity. The first step in management involves reviewing and possibly discontinuing or switching the antipsychotic medication. In many cases, switching to atypical antipsychotics, which have a lower risk of tardive dyskinesia, can be beneficial. Additionally, agents such as VMAT2 inhibitors (eg, valbenazine or deutetrabenazine) are approved for treating tardive dyskinesia. During pregnancy and lactation, treatment must be approached cautiously given the potential risks to the fetus or infant, with a multidisciplinary consultation to weigh risks versus benefits. Option A (Tardive dyskinesia) is correct as it directly points to the most likely diagnosis given the patient\u2019s history of prolonged antipsychotic exposure in a psychiatric hospital. Other options are not provided, but the clinical scenario strongly supports this diagnosis. 1. Tardive dyskinesia typically develops after prolonged antipsychotic use and is more common with first-generation agents. 2. Early detection is key, as tardive dyskinesia may be irreversible if not managed promptly. 3. VMAT2 inhibitors have emerged as an effective treatment option. Recent clinical guidelines recommend early intervention upon the recognition of tardive dyskinesia. Newer pharmacologic agents, specifically VMAT2 inhibitors, have shown significant efficacy and safety profiles and are increasingly recommended over older, less effective treatments.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of girl with dystonia, no Parkinsonism features.",
    "option_a": "DYT 1",
    "option_b": "DYT 5 (GCH1)",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "This scenario describes a young girl with dystonia in the absence of Parkinsonism. Dopa-responsive dystonia (DRD), also known as Segawa syndrome, is an autosomal dominant condition that frequently presents in childhood \u2013 particularly in girls \u2013 with predominantly dystonic features that show diurnal variability and a dramatic response to levodopa therapy. It is designated as DYT5, indicating its genetic classification. DRD is most commonly caused by mutations in the GCH1 gene, which encodes GTP cyclohydrolase I. This enzyme is critical for the synthesis of tetrahydrobiopterin (BH4), an essential cofactor for tyrosine hydroxylase\u2014the rate\u2010limiting enzyme in dopamine synthesis. The resulting deficit leads to a selective dopamine deficiency in the basal ganglia, causing dystonic movements without the classic features of Parkinsonism (eg, tremor, rigidity, bradykinesia) seen when nigrostriatal degeneration is present. Patients with DRD typically present during childhood with gait disturbances, limb dystonia (often starting in the lower extremities), and sometimes postural abnormalities. A key clinical clue is the marked diurnal variation, with symptoms worsening as the day progresses, and the dramatic improvement with low\u2010dose levodopa distinguishes this condition from other forms of early-onset dystonia. The diagnosis is suggested by the clinical history and response to low-dose levodopa. Differential diagnoses include early-onset DYT1 dystonia (which usually does not exhibit a marked levodopa response) and other forms of childhood-onset movement disorders such as cerebral palsy. Genetic testing confirming a mutation in GCH1 supports the diagnosis of DYT5 (DRD). Neuroimaging is typically normal. The first-line treatment for DRD is low-dose levodopa, which usually results in marked and sustained improvement in symptoms. Current guidelines recommend levodopa therapy as the treatment of choice. In pregnancy and lactation, levodopa is generally considered safe under close supervision; however, close monitoring and multidisciplinary management are recommended to balance maternal symptom control with fetal safety. Option A (DYT1) is typically associated with early-onset generalized dystonia that is often less responsive to levodopa and has a different genetic basis (TOR1A mutation). Option B (DYT5, due to GCH1 mutation) correctly identifies the dopa-responsive dystonia scenario in a girl. Options C and D are not provided. 1. DRD (DYT5) presents with childhood-onset dystonia, often with a marked diurnal fluctuation and an excellent response to low-dose levodopa. 2. The absence of parkinsonian features (eg, tremor, rigidity) helps distinguish it from other dopaminergic disorders. 3. Genetic testing for GCH1 mutations can confirm the diagnosis. Recent studies have reinforced the diagnostic value of a levodopa trial in suspected DRD cases and emphasize early genetic testing to differentiate DRD from other dystonias. Updated clinical guidelines continue to support levodopa as the first-line treatment, with excellent long-term outcomes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "A 67-year-old man with a 3-year history of Parkinson disease has had increasingly distressing problems with visual and auditory hallucinations and very severe and disturbing delusions. Which of the following medications is US Food and Drug Administration (FDA) approved for treatment of these symptoms in Parkinson disease?",
    "option_a": "clozapine",
    "option_b": "lurasidone",
    "option_c": "pimavanserin",
    "option_d": "quetiapine",
    "option_e": "ziprasidone",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "This scenario describes a young girl with dystonia in the absence of Parkinsonism. Dopa-responsive dystonia (DRD), also known as Segawa syndrome, is an autosomal dominant condition that frequently presents in childhood \u2013 particularly in girls \u2013 with predominantly dystonic features that show diurnal variability and a dramatic response to levodopa therapy. It is designated as DYT5, indicating its genetic classification. DRD is most commonly caused by mutations in the GCH1 gene, which encodes GTP cyclohydrolase I. This enzyme is critical for the synthesis of tetrahydrobiopterin (BH4), an essential cofactor for tyrosine hydroxylase\u2014the rate\u2010limiting enzyme in dopamine synthesis. The resulting deficit leads to a selective dopamine deficiency in the basal ganglia, causing dystonic movements without the classic features of Parkinsonism (eg, tremor, rigidity, bradykinesia) seen when nigrostriatal degeneration is present. Patients with DRD typically present during childhood with gait disturbances, limb dystonia (often starting in the lower extremities), and sometimes postural abnormalities. A key clinical clue is the marked diurnal variation, with symptoms worsening as the day progresses, and the dramatic improvement with low\u2010dose levodopa distinguishes this condition from other forms of early-onset dystonia. The diagnosis is suggested by the clinical history and response to low-dose levodopa. Differential diagnoses include early-onset DYT1 dystonia (which usually does not exhibit a marked levodopa response) and other forms of childhood-onset movement disorders such as cerebral palsy. Genetic testing confirming a mutation in GCH1 supports the diagnosis of DYT5 (DRD). Neuroimaging is typically normal. The first-line treatment for DRD is low-dose levodopa, which usually results in marked and sustained improvement in symptoms. Current guidelines recommend levodopa therapy as the treatment of choice. In pregnancy and lactation, levodopa is generally considered safe under close supervision; however, close monitoring and multidisciplinary management are recommended to balance maternal symptom control with fetal safety. Option A (DYT1) is typically associated with early-onset generalized dystonia that is often less responsive to levodopa and has a different genetic basis (TOR1A mutation). Option B (DYT5, due to GCH1 mutation) correctly identifies the dopa-responsive dystonia scenario in a girl. Options C and D are not provided. 1. DRD (DYT5) presents with childhood-onset dystonia, often with a marked diurnal fluctuation and an excellent response to low-dose levodopa. 2. The absence of parkinsonian features (eg, tremor, rigidity) helps distinguish it from other dopaminergic disorders. 3. Genetic testing for GCH1 mutations can confirm the diagnosis. Recent studies have reinforced the diagnostic value of a levodopa trial in suspected DRD cases and emphasize early genetic testing to differentiate DRD from other dystonias. Updated clinical guidelines continue to support levodopa as the first-line treatment, with excellent long-term outcomes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Same scenario, what is next?",
    "option_a": "Start levodopa",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "This scenario is presumed to describe a patient with a typical Parkinson\u2019s disease (PD) presentation\u2014characterized by bradykinesia, rigidity, tremor, and possibly postural instability. In managing PD, once the clinical diagnosis has been established and if the patient is symptomatic enough to impact quality of life, the mainstay of therapy is dopaminergic treatment. Levodopa remains the most effective option for symptomatic control in PD, especially in older patients. Parkinson\u2019s disease is marked by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to reduced dopamine levels in the striatum. This neurotransmitter deficiency disrupts the normal balance of the basal ganglia circuitry, resulting in the characteristic motor symptoms observed in PD. Patients with PD typically present with motor symptoms that progressively worsen over time. In typical practice, the decision to initiate treatment with levodopa is based on the severity of symptoms. In older patients or those with significant functional impairment, levodopa is favored because of its superior efficacy. It is important to recognize that in certain subgroups (for example, younger patients) other agents like dopamine agonists might be preferred initially to delay levodopa\u2010related motor complications. The diagnosis of PD is predominantly clinical. A detailed neurological examination that reveals bradykinesia with at least one of resting tremor or rigidity supports the diagnosis. Differential diagnoses include atypical parkinsonian syndromes (such as multiple system atrophy or progressive supranuclear palsy), drug-induced parkinsonism, and essential tremor. In uncertain cases, ancillary studies such as a dopamine transporter (DaT) scan may be considered. Based on the latest clinical guidelines, levodopa is the gold standard for the treatment of PD motor symptoms. For patients with significant impairment, initiating levodopa therapy is recommended. In patients of childbearing age or those who are pregnant/lactating, the risks and benefits must be carefully weighed. Levodopa is considered relatively safe during pregnancy when the benefits justify its use and, with lactation, monitoring is required given the potential for passage into breast milk. Non-pharmacological interventions such as exercise and physical therapy are also recommended alongside drug therapy. Option A, 'Start levodopa,' directly addresses the need to initiate symptomatic treatment for a patient diagnosed with Parkinson\u2019s disease\u2014a decision supported by robust evidence and guidelines. The remaining options (B, C, and the marked option D) are either not specified or lack the necessary evidence to justify their use. This makes option A the most evidence-based and appropriate next step in management, indicating that the marked answer (D) is incorrect. \u2022 Levodopa remains the most effective treatment for controlling PD motor symptoms.\n\u2022 Early initiation of appropriate therapy can improve quality of life. \n\u2022 Treatment choice must be individualized based on patient age, severity of symptoms, and risk of motor complications.\n\u2022 In pregnant or lactating patients, therapy should be as conservative as possible and involve shared decision-making after discussing the risks and benefits. Recent clinical studies and guidelines from the Movement Disorder Society reinforce levodopa\u2019s role as the first-line treatment for symptomatic PD in appropriate patient populations. While some debate remains regarding initial treatment in younger patients (to delay levodopa-induced dyskinesias), the overall body of evidence supports levodopa as the most potent agent for motor symptom relief. When considering therapy during pregnancy and lactation, current recommendations emphasize the cautious use of levodopa after a thorough risk\u2013benefit evaluation.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Dystonia with myoclonus",
    "option_a": "SCG1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Myoclonus-dystonia syndrome is characterized by the coexistence of dystonia (sustained or repetitive muscle contractions causing twisting and abnormal postures) with myoclonus (sudden, brief, involuntary jerks). It is typically an autosomal dominant disorder with variable penetrance, most commonly associated with mutations in the SGCE gene. Although the option is labeled 'SCG1', it appears to be a reference to the gene product involved in this syndrome, which is well known as SGCE (epsilon-sarcoglycan). Mutations in the SGCE gene disrupt the normal function of epsilon-sarcoglycan, a component of the dystrophin-associated glycoprotein complex. This disruption impairs neuronal signaling within basal ganglia circuits responsible for the regulation of movement, leading to abnormal modulation of motor control and the development of both dystonic postures and myoclonic jerks. Patients typically present with a combination of rapid, shock\u2010like myoclonic jerks and sustained dystonic posturing. Symptoms often begin in childhood or early adulthood. A noteworthy clinical clue is that some patients report transient improvement of symptoms with alcohol ingestion. Family history may reveal autosomal dominant inheritance, sometimes with paternal imprinting affecting penetrance. The diagnosis is primarily clinical, based on the characteristic presentation of combined dystonia and myoclonus. A detailed family history is important. Neuroimaging is usually unremarkable, so genetic testing for SGCE mutations is key to confirm the diagnosis and distinguish it from other movement disorders that may present similarly. Differential diagnoses include other forms of dystonia, myoclonic epilepsies, and metabolic disorders. Treatment is principally symptomatic. First-line therapies include benzodiazepines (such as clonazepam), anticholinergics, and sometimes levodopa. Botulinum toxin injections can be useful for focal dystonic manifestations. In refractory cases, deep brain stimulation (DBS) targeting the globus pallidus internus (GPi) has shown benefit. In pregnancy and lactation, the use of pharmacologic agents must be carefully weighed against potential risks. For instance, clonazepam is categorized as pregnancy category D in some jurisdictions, so its use requires a careful risk-benefit discussion. Non-pharmacologic management and multidisciplinary consultation (including neurology, obstetrics, and neonatology) are recommended to optimize outcomes. The marked answer option 'A: SCG1' is interpreted as referring to the SGCE gene involved in myoclonus-dystonia syndrome. Despite the slight nomenclature discrepancy, it correctly identifies the genetic basis for the condition. The absence of other options limits comparative analysis, but current literature supports SGCE mutation as the principal implicated factor. \u2022 Myoclonus-dystonia syndrome often presents in childhood or early adulthood with combined myoclonic and dystonic features. \n\u2022 A unique feature is the reported improvement with alcohol ingestion. \n\u2022 It is inherited in an autosomal dominant fashion with variable penetrance due to imprinting. \n\u2022 Genetic testing for SGCE mutations is critical for diagnosis. Recent studies and clinical guidelines emphasize the pattern of SGCE mutations in patients with myoclonus-dystonia. Advances in genetic testing have improved diagnostic accuracy. Moreover, emerging evidence supports the use of DBS in refractory cases, and current management strategies underscore the importance of individualized therapy, particularly when considering treatment during pregnancy and lactation. Ongoing research continues to refine both pharmacologic and non-pharmacologic management options.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Sydenham in girl:",
    "option_a": "ASO titer",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Sydenham chorea is a neuropsychiatric manifestation of acute rheumatic fever that typically occurs in children, especially girls. Its diagnosis is often supported by evidence of a preceding group A streptococcal infection \u2013 for which the antistreptolysin-O (ASO) titer is a key laboratory marker. The condition is thought to result from an autoimmune reaction in which antibodies produced against streptococcal antigens cross-react with basal ganglia neurons. This autoimmune cross-reactivity leads to abnormal neurotransmission and results in involuntary, rapid, and irregular movements. Patients, often young girls, present with involuntary, purposeless, and rapid choreiform movements of the limbs. There can also be emotional lability and muscle weakness. An elevated ASO titer confirms a recent streptococcal infection, thereby helping to link the movement disorder to rheumatic fever. Diagnosis is mainly clinical using Jones criteria for rheumatic fever. Laboratory investigations include measuring the ASO titer, anti-DNase B levels, and, when indicated, throat cultures. Differential diagnoses include other causes of chorea such as Huntington\u2019s disease, Wilson\u2019s disease, and drug-induced dyskinesias, which can be differentiated based on age, family history, associated clinical findings, and laboratory studies. Management involves supportive care and symptomatic treatment. In addition to anti-inflammatory or immunomodulatory treatments in selected severe cases (e.g., corticosteroids), prophylactic antibiotics (typically penicillin) are used to prevent recurrent streptococcal infections. In terms of safety, penicillin is considered safe during pregnancy and lactation, and any additional symptomatic treatment must be chosen based on risk\u2010benefit analyses specific to pediatric or pregnant patients. Option A (ASO titer) is correct because measuring the ASO titer is a crucial step in supporting the diagnosis of Sydenham chorea by confirming a recent streptococcal infection. The absence of further options might indicate that the focus was on this important laboratory test. 1) Sydenham chorea is more frequently seen in girls and is a late manifestation of rheumatic fever. 2) The ASO titer is a sensitive marker for recent group A streptococcal infection. 3) Management not only focuses on treating the movement disorder but also on preventing further streptococcal infections. Recent guidelines emphasize early detection of streptococcal infection and aggressive management with prophylactic antibiotics to prevent rheumatic fever complications. While the symptomatic management of chorea is largely supportive, ongoing research continues to evaluate immunomodulatory treatments in severe cases.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Essential tremor and asthma:",
    "option_a": "Primidone",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential tremor is one of the most common movement disorders that typically presents with an action or postural tremor. The standard first\u2010line treatment is a non\u2010selective beta\u2010blocker like propranolol; however, the presence of asthma represents a contraindication to beta-blockers due to their risk of precipitating bronchospasm. The pathogenesis of essential tremor involves abnormal oscillatory activity within the cerebellothalamocortical circuit. Although the exact mechanism is unclear, there is evidence of both genetic and environmental influences leading to neuronal hyperexcitability. Patients with essential tremor present with rhythmic shaking of the hands or head that worsens with voluntary movement. In asthmatic patients, beta-blockers may exacerbate bronchospasm, making them a less suitable choice. Diagnosis of essential tremor is typically clinical. Differential diagnoses include Parkinson\u2019s disease (which features resting tremor), enhanced physiologic tremor, and dystonic tremor. A detailed history and neurological exam help differentiate these conditions. For patients without contraindications, beta-blockers (especially propranolol) are usually first-line. In asthmatic individuals, primidone is considered a first-line alternative. For women who are pregnant or lactating, the risk\u2013benefit profile of primidone must be carefully considered since data in pregnancy are limited and both beta-blockers and primidone carry potential risks; treatment is typically individualized with close monitoring. Option A (Primidone) is the correct choice here because it serves as an effective alternative to beta-blockers in patients with essential tremor who also have asthma. The other options are not provided, focusing attention on the key contraindication and alternative. 1) Asthma is a key contraindication for beta-blocker use in essential tremor. 2) Primidone is a viable alternative and has been shown to reduce tremor amplitude in essential tremor patients. 3) Always correlate treatment choice with patient comorbidities. Recent studies continue to support primidone\u2019s efficacy in essential tremor management for patients with pulmonary disease. Updated guidelines underscore the importance of individualized therapy, particularly in patients with significant comorbid conditions such as asthma.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Sydenham chorea treatment:",
    "option_a": "Haloperidol",
    "option_b": "Valproic acid",
    "option_c": "CMZ",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Sydenham chorea is a movement disorder associated with acute rheumatic fever, characterized by rapid, involuntary movements due to autoimmune injury to the basal ganglia. Treatment is predominantly supportive and symptomatic. Following a group A streptococcal infection, an autoimmune response develops. Antibodies mistakenly attack neuronal tissue in the basal ganglia, leading to dysregulated dopaminergic transmission and resulting in choreatic movements. Clinically, affected children (more commonly girls) present with rapid, purposeless jerks and emotional lability. In severe cases, the chorea can interfere with daily activities and may require pharmacotherapy. Diagnosis is based on a combination of clinical findings and supporting laboratory evidence (e.g., elevated ASO titers). It is important to distinguish Sydenham chorea from other causes of chorea such as Wilson\u2019s disease or drug-induced dyskinesias, using laboratory tests and imaging studies as needed. The management of Sydenham chorea is mainly supportive. Symptomatic treatment options include dopamine receptor antagonists such as haloperidol, which has been widely used despite potential side effects. Alternatives include valproic acid or carbamazepine (CMZ) in cases where haloperidol\u2019s side effects are intolerable. In pregnant patients, haloperidol is classified as Category C; its use should be justified with a careful risk\u2013benefit analysis, and alternative agents may be considered if available. Option A (Haloperidol) is correct as it is one of the most commonly used agents in the symptomatic treatment of Sydenham chorea. Option B (Valproic acid) and Option C (CMZ, likely referring to carbamazepine) are also used in some clinical scenarios but are generally considered alternatives if haloperidol is contraindicated or poorly tolerated. 1) Sydenham chorea is typically a self-limited condition but may cause significant disability requiring symptomatic treatment. 2) Haloperidol, despite its side effects, has long been used effectively for chorea. 3) Alternative agents like valproic acid may be considered with caution, especially in women of childbearing age due to teratogenic risks. Although haloperidol remains a mainstay of symptomatic treatment, recent research emphasizes the role of individualized therapy and the potential benefit of newer agents with more favorable side effect profiles. Updated guidelines continue to support a tailored approach depending on patient age, severity of symptoms, and comorbid conditions.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Orthostatic tremor not tolerating clonazepam, what is the second line?",
    "option_a": "Propranolol",
    "option_b": "Levodopa",
    "option_c": "Pramipexol",
    "option_d": "Trihexyphenidyl",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor is a rare movement disorder characterized by high-frequency tremors in the legs that occur exclusively on standing and typically subside on sitting or walking. Clonazepam is usually the first-line treatment; however, when a patient cannot tolerate it, a second-line agent is needed. The tremor is thought to arise from a central oscillator, possibly within the cerebellothalamocortical network, resulting in a rapid, rhythmic contraction of leg muscles. The exact etiology remains unclear, though it is distinct from more common tremor disorders. Patients experience unsteadiness and a feeling of leg shaking when standing, often leading to fear of falling. The tremor frequency is generally in the 13\u201318 Hz range, which can be confirmed through electromyography (EMG). Differential diagnoses include essential tremor and Parkinsonian tremors, but these typically present with different characteristics and distributions. Diagnosis is primarily clinical and is supported by EMG findings that document the high-frequency tremor. It is important to differentiate orthostatic tremor from other conditions such as essential tremor (which typically affects the hands and is present during action) and Parkinson\u2019s disease (which includes bradykinesia and resting tremor). The first-line treatment is clonazepam. For patients who are intolerant to clonazepam, beta-blockers (e.g., propranolol) have been used as a second-line treatment, particularly given their established role in managing various tremor syndromes. In pregnant or lactating patients, propranolol (a beta-blocker) is generally classified as Category C; if used, the lowest effective dose should be administered with close monitoring of both maternal and fetal well-being. Option A (Propranolol) is the best available second-line option among those provided, as beta-blockers are sometimes effective in tremor management. Option B (Levodopa) and Option C (Pramipexol) are dopamine-related medications typically used in Parkinson\u2019s disease, while Option D (Trihexyphenidyl) is an anticholinergic used in Parkinsonism; none of these are standard treatments for orthostatic tremor. 1) Orthostatic tremor is uniquely characterized by high-frequency leg tremors that occur only while standing. 2) EMG is a useful diagnostic tool for confirming the high-frequency nature of the tremor. 3) When clonazepam is not tolerated, propranolol is a reasonable second-line choice, even though evidence is based on limited case series. The management of orthostatic tremor remains challenging due to the rarity of the condition and the paucity of large clinical trials. Recent case reports and small studies support the use of clonazepam as first-line therapy and suggest that beta-blockers such as propranolol may be beneficial as second-line agents. Ongoing research continues to explore additional therapeutic options and to better delineate the underlying pathophysiology.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Palatal abnormal movements fast rhythmic persisting during sleep (clicking was not Mentioned)",
    "option_a": "Symptomatic palatal myoclonus",
    "option_b": "Essential palatal myoclonus",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Palatal myoclonus refers to involuntary, rhythmic movements of the muscles of the soft palate. It is broadly classified into two types: symptomatic palatal myoclonus, which is secondary to a structural lesion (typically within the Guillain-Mollaret triangle), and essential palatal myoclonus, which is idiopathic and often accompanied by an audible clicking sound. Symptomatic palatal myoclonus is caused by lesions that affect the dentato-rubro-olivary pathway. This disruption leads to degeneration or hypertrophy in the inferior olivary nucleus, resulting in persistent, rhythmic contractions. In contrast, essential palatal myoclonus does not have an identifiable structural lesion, and its mechanism is less well-understood. A key difference is that the symptomatic type typically persists during sleep and does not produce an audible click, whereas the essential type frequently is associated with clicking noises due to involvement of the tensor veli palatini muscle. Patients with symptomatic palatal myoclonus present with fast, rhythmic palatal movements that continue into sleep, without the clicking sound commonly reported in the essential variant. The persistence during sleep is a significant clinical clue pointing toward a structural lesion causing the phenomenon. The diagnosis is largely clinical but is supported by neuroimaging, usually MRI, to evaluate for lesions in the Guillain-Mollaret triangle (which includes the dentate nucleus, red nucleus, and inferior olivary nucleus). Differential diagnoses include essential palatal tremor (where a click is noted and movements may diminish during sleep) as well as other myoclonic disorders. Careful history and neurologic examination help distinguish these entities. The treatment of symptomatic palatal myoclonus focuses on addressing the underlying lesion when possible. Symptomatic management can include pharmacotherapy (with agents such as clonazepam or other muscle relaxants) or targeted interventions like botulinum toxin injections to reduce muscle activity. In pregnant or lactating patients, nonpharmacologic approaches or medications with proven safety profiles in pregnancy (after appropriate risk\u2010benefit assessment) should be considered. Option A (Symptomatic palatal myoclonus) is correct because the description of movements that persist during sleep and the absence of clicking strongly indicate a lesion-induced, symptomatic form. Option B (Essential palatal myoclonus) would be more likely if an audible click were present and if the movements diminished during sleep. 1. Symptomatic palatal myoclonus is usually due to lesions in the Guillain-Mollaret triangle and persists during sleep. 2. Essential palatal myoclonus is often accompanied by an audible clicking sound. 3. Neuroimaging is essential to distinguish between these two entities. Recent studies have reinforced the role of the dentato-rubro-olivary pathway in symptomatic palatal myoclonus and suggest targeted therapies (including botulinum toxin) may improve patient outcomes, although addressing the primary lesion remains paramount.",
    "exam_year": "2019",
    "exam_type": "Part I"
  }
]